Welcome to our dedicated page for JATT II Acquisition SEC filings (Ticker: JATT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
JATT II Acquisition Corp filings document the regulatory record of a Cayman Islands SPAC with Nasdaq-listed ordinary shares. The company’s Form 8-K disclosures report its initial public offering, ordinary-share capitalization, material definitive agreements, underwriter over-allotment arrangements and exchange listing under the symbol JATT.
The filing record also identifies governance and issuer-status matters, including emerging growth company status, Section 12(b) registration of the ordinary shares and other public-company disclosures associated with a blank-check company pursuing a business combination.
Great Point Partners, LLC together with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl report beneficial ownership of 500,000 ordinary shares of JATT II Acquisition Corp., representing 6.41% of the class. The percentage is calculated using 7,800,000 shares outstanding as reported in the issuer's Form 424B prospectus filed April 17, 2026. Great Point is the investment manager of two record holders—Biomedical Value Fund, L.P. (330,000 shares) and Biomedical Offshore Value Fund, Ltd. (170,000 shares)—and Dr. Jay and Ms. Nordahl have shared voting and dispositive power over the 500,000 shares; they disclaim beneficial ownership except for pecuniary interests.
JATT Ventures II L.P., the sponsor of JATT II Acquisition Corp., reported an open-market style private transaction to acquire 300,000 Ordinary Shares at a stated price of $0.0000 per share. These are private placement shares purchased under a Private Placement Shares Purchase Agreement dated April 16, 2026.
Following this transaction, JATT Ventures II L.P. holds 2,025,000 Ordinary Shares, including up to 225,000 Ordinary Shares that are subject to potential forfeiture depending on the underwriter’s over-allotment option from the company’s initial public offering.
JATT II Acquisition Corp. director and CEO Dr. Someit Sidhu reported an indirect open-market style purchase linked to the company’s sponsor. An affiliated entity, JATT Ventures II L.P., bought 300,000 ordinary shares as private placement shares under an agreement dated April 16, 2026. Following this transaction, Dr. Sidhu is reported as having indirect ownership of 2,025,000 ordinary shares through the sponsor structure. The filing notes that up to 225,000 ordinary shares are subject to possible forfeiture depending on how the underwriter’s over-allotment option from the IPO was exercised, and Dr. Sidhu disclaims beneficial ownership beyond his economic interest.
JATT II Acquisition Corp completed its initial public offering of 6,000,000 ordinary shares at $10.00 per share, generating gross proceeds of $60,000,000. Underwriters have a 45-day option to buy up to 900,000 additional shares at the same price.
At the IPO closing, the sponsor bought 300,000 private placement shares at $10.00 each, adding $3,000,000. A total of $60,000,000 from the IPO and private placement was deposited into a U.S.-based trust account to fund a future business combination, subject to specified redemption and charter amendment conditions.
In connection with the IPO, the company appointed four independent directors, constituted its board committees, and adopted an amended and restated charter in the Cayman Islands. JATT II is a healthcare-focused special purpose acquisition company targeting biotechnology and life sciences businesses.
JATT II Acquisition Corp. director Christopher Staral filed an initial ownership report on Ordinary Shares. The filing shows indirect ownership of 25,000 founder shares, held through membership interests in the company’s sponsor, JATT Ventures II L.P., received as compensation for his director services, with no reported buy or sell transaction.
JATT II Acquisition Corp. director Arjun Goyal has filed an initial Form 3 reporting an indirect holding of 25,000 Ordinary Shares. These shares are held through his membership interests in the company’s sponsor, JATT Ventures II L.P., reflecting founder share compensation for his director services. The filing does not report any new share purchases or sales, only the existing indirect position.
JATT II Acquisition Corp. director Jonathon Kluft filed an initial ownership report on Form 3. The filing shows an indirect holding of 25,000 Ordinary Shares, recorded as of the reported date. These shares reflect founder-related interests received through the company’s sponsor rather than a new market transaction.
JATT II Acquisition Corp. director and Chief Financial Officer Nicholas Fernandez filed an initial ownership report showing an indirect interest in 50,000 Ordinary Shares.
According to a footnote, this interest comes through founder shares held via membership interests in the company’s sponsor, JATT Ventures II L.P., rather than directly owned stock.
JATT II Acquisition Corp. insider JATT Ventures II L.P. filed an initial Form 3 disclosing its ownership in the company’s ordinary shares. The filing reports direct ownership of 1,725,000 Ordinary Shares, establishing JATT Ventures II L.P. as a ten percent owner of the company.
The footnotes explain that JATT Ventures II Ltd is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is both a limited partner of JATT Ventures II L.P. and the sole member of JATT Ventures II Ltd. Dr. Sidhu has voting and investment discretion over these shares but disclaims beneficial ownership except for any pecuniary interest.